Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mirivadelgat - Foresee Pharmaceuticals

Next Previous
X
Search
Drug Profile

Mirivadelgat - Foresee Pharmaceuticals

Alternative Names: FP-045; FRS 045

Latest Information Update: 10 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Foresee Pharmaceuticals
  • Class Antianaemics; Cardiovascular therapies; Hepatoprotectants; Small molecules
  • Mechanism of Action Aldehyde dehydrogenase 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Fanconi's anaemia
  • Phase I Cardiovascular disorders; Kidney disorders; Metabolic disorders; Pulmonary hypertension
  • No development reported Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 04 Dec 2024 Foresee Pharmaceuticals plans the phase II WINDWARD trial for Pulmonary hypertension (PO), in first quarter of 2025
  • 29 Apr 2024 Pharmacodynamics data from a preclinical trial in Pulmonary hypertension associated interstitial lung disease released by Foresee Pharmaceuticals
  • 12 Oct 2023 FP 045 is still in phase-I trials for Cardiovascular disorders in USA (Foresee Pharmaceutical pipeline; October 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top